Sugi Predict

Sugi Predict / Compounds / SCHEMBL2524652

SCHEMBL2524652

SCHEMBL2524652

CC1(C)OB(c2ccc(C3CC3)cc2F)OC1(C)C

nearest known ligand 0.36

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 2/20 0.36
▸ LIPG Q9Y5X9 2/20 0.36
▸ HIF1A Q16665 1/20 0.32
▸ ESR1 P03372 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ JAK2 O60674 1/20 0.31
▸ BTK Q06187 1/20 0.31
▸ HRH3 Q9Y5N1 4/20 0.31
▸ ROCK1 Q13464 1/20 0.30
▸ P2RX7 Q99572 1/20 0.30
▸ RORC P51449 1/20 0.30
▸ PDK2 Q15119 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30945238 1.00 LPL (0.36) LPLLIPGHIF1AESR1ESR2
SCHEMBL26991546 0.93 HIF1A (0.39) LPLLIPGHIF1AJAK2BTK
Heptane SCHEMBL28183875 0.91 LPL (0.41) LPLLIPG
SCHEMBL31222912 0.90 QDPR (0.41) HRH3
SCHEMBL24802990 0.89 QDPR (0.44) HRH3
SCHEMBL31223008 0.89 QDPR (0.44) HRH3
SCHEMBL24658423 0.85 JAK2 (0.33) LPLLIPGJAK2BTKROCK1
SCHEMBL15031645 0.83 HIF1A (0.33) LPLLIPGHIF1AESR2P2RX7
SCHEMBL29891190 0.82 HIF1A (0.35) LPLLIPGHIF1AJAK2BTK
SCHEMBL24746032 0.82 HIF1A (0.35) LPLLIPGHIF1AJAK2BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS GIVAUDAN SA (CH) 2026-04-16 — — US disclosed
US-12528801-B2 Substituted azacyles as TRPM8 modulators GIVAUDAN SA (CH) 2026-01-20 — — US disclosed
US-20250340563-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2025-11-06 — — US disclosed
CN-114555594-B Substituted azacycles as TRMP modulators 奇华顿股份有限公司 2025-03-18 — — CN disclosed
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2024-04-25 — — US disclosed
WO-2023194964-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-12 — — WO disclosed
EP-3784667-B1 HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2023-08-16 — — EP disclosed
EP-4045491-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS Givaudan SA (CH) 2022-08-24 — — EP disclosed
CN-114555594-A Substituted azaheterocycles as TRMP8 modulators 奇华顿股份有限公司 2022-05-27 — — CN disclosed
WO-2021074281-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2021-04-22 — — WO disclosed
WO-2013045461-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-04-04 — — WO disclosed
WO-2013045461-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2013-04-04 — — WO disclosed
US-20130079321-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2013-03-28 — — US disclosed
US-20130079321-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2013-03-28 — — US disclosed
EP-2556066-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE F. Hoffmann-La Roche AG (CH) 2013-02-13 — — EP disclosed
WO-2011124580-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-10-13 — — WO disclosed
WO-2011124580-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2011-10-13 — — WO disclosed
US-20110251176-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2011-10-13 — — US disclosed
US-20110251176-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2011-10-13 — — US disclosed
US-20110251176-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE GENENTECH, INC. 2011-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103459-A1 SUBSTITUTED AZACYLES AS TRPM8 MODULATORS TRPM8, TRPM7, TRPM5 LPL 2835/4885LIPG 2646/4885HIF1A 2211/4885
US-20110251176-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE PIM1, PIM2, PIM3 LPL 4807/4885LIPG 4521/4885HIF1A 1089/4885
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS TRPM8, TRPM7, TRPM5 LPL 3459/4885LIPG 2199/4885HIF1A 4008/4885
US-12528801-B2 Substituted azacyles as TRPM8 modulators TRPM8, TRPM7, TRPM4 LPL 2903/4885LIPG 3062/4885HIF1A 2637/4885
US-20250340563-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS NLRP3, NLRP1, NOD1 LPL 3144/4885LIPG 4256/4885HIF1A 2638/4885
US-20130079321-A1 PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE PIM1, PIM2, PIM3 LPL 4822/4885LIPG 4427/4885HIF1A 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.